¼¼°èÀÇ ½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á ½ÃÀå : ¿¹Ãø - Ä¡·á À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(-2032³â)
Personalized Medicine in Neurology Market Forecasts to 2032 - Global Analysis By Therapy Type (Pharmacogenomics, Digital Therapeutics, Biomarker-Based Diagnostics and Targeted Therapeutics), Technology, Application, End User and By Geography
»óǰÄÚµå : 1822447
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 5,968,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,551,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 9,133,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,787,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á ½ÃÀåÀº 2025³â¿¡ 5,768¾ï ´Þ·¯·Î ÃßÁ¤µÇ°í, ¿¹Ãø ±â°£ µ¿¾È CAGR 8.5%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2032³â¿¡´Â 1Á¶ 211¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á´Â Áø´Ü, Ä¡·á ¹× ¿¹¹æ Àü·«À» °³Àκ° À¯ÀüÀÚ, ¹ÙÀÌ¿À¸¶Ä¿, ȯ°æ, ¶óÀÌÇÁ½ºÅ¸ÀÏ ÇÁ·ÎÆÄÀÏ¿¡ ¸Â°Ô Á¶Á¤Çϴ ȯÀÚ Á᫐ Á¢±Ù¹ýÀÔ´Ï´Ù. À¯ÀüüÇÐ, ´º·Î À̹Ì¡, µ¥ÀÌÅÍ ºÐ¼® µîÀÇ Ã·´Ü ±â¼úÀ» ÅëÇÕÇÏ°í °³ÀÎ ¼öÁØ¿¡¼­ Áúº´ÀÇ ¸ÞÄ¿´ÏÁòÀ» ÀÌÇØÇÔÀ¸·Î½á 'ȹÀÏÀûÀÎ' ¸ðµ¨À» ÃÊ¿ùÇÕ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº °£Áú, ¾ËÃ÷ÇÏÀ̸Ӻ´, ´Ù¹ß¼º °æÈ­Áõ°ú °°Àº ½Å°æ Áúȯ °ü¸®ÀÇ Á¤È®¼ºÀ» ³ôÀÌ°í °á°ú¸¦ °³¼±ÇÏ¸ç ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ¸ÂÃãÇü ½Å°æÇÐÀº ¶ÇÇÑ Á¶±â ¹ß°ß ¹× Ç¥Àû Ä¡·á¸¦ ÃËÁøÇϰí ÀÓ»ó°¡¿¡°Ô º¸´Ù È¿°úÀûÀÌ°í ¿¹Ãø °¡´ÉÇÑ °¢ ȯÀÚÀÇ ½Å°æÇÐÀû üÁú¿¡ ´ëÀÀÇÏ´Â Ä¡·á¸¦ Á¦°øÇÏ´Â ´É·ÂÀ» Á¦°øÇÕ´Ï´Ù.

½Å°æ ÁúȯÀÇ À¯º´·ü »ó½Â

½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¸ÂÃãÇü ÀÇ·áÀÇ Áøº¸¸¦ °¡¼ÓÈ­ÇÏ°í ½Å°æÇÐÀ» º¸´Ù Á¤¹ÐÇϰí ȯÀÚ Áß½ÉÀÇ ºÐ¾ß·Î ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¬±¸ÀÚµéÀº À¯ÀüÀÚ, ¹ÙÀÌ¿À¸¶Ä¿, ¶óÀÌÇÁ½ºÅ¸ÀÏ µ¥ÀÌÅ͸¦ Ȱ¿ëÇÏ¿© ¾ËÃ÷ÇÏÀ̸Ӻ´°ú ÆÄŲ½¼º´°ú °°Àº Áúº´ÀÇ Ä¡·á¸¦ ¸ÂÃãÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â Áø´Ü°ú Ä¡·áÀÇ Çõ½ÅÀ» ÃËÁøÇϰí ÀÓ»óÀǰ¡ º¸´Ù È¿°úÀûÀÌ°í °³ÀÎÈ­µÈ Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖ°Ô Çϰí, °á±¹ ½Å°æ ÁúȯÀ» ¾Î°í ÀÖ´Â ¼ö¹é¸¸ ¸íÀÇ »ç¶÷µéÀÇ °á°ú¿Í »îÀÇ ÁúÀ» Çâ»ó½Ãŵ´Ï´Ù.

¸ÂÃãÇü ÀÇ·áÀÇ ³ôÀº ºñ¿ë

½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °í°¡ÀÇ ºñ¿ëÀº Ä¡·á Á¢±Ù°ú °øÁ¤¼ºÀ» ÇöÀúÇÏ°Ô ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº ȯÀÚ, ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­´Â °í±Þ À¯Àüü °Ë»ç ¹× ¸ÂÃãÇü ÀǷḦ ¹ÞÀ» ¿©À¯°¡ ¾ø¾î Ä¡·á ¼ºÀû¿¡ °ÝÂ÷°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. ÀÌ °æÁ¦Àû À庮Àº È®»êÀ» ´ÊÃß°í ÀÓ»ó½ÃÇèÀ» Á¦ÇÑÇϸç È®Àå °¡´ÉÇÑ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ¸¦ ¹æÇØÇÕ´Ï´Ù. ±Ã±ØÀûÀ¸·Î ¸ðµç »ç¶÷¿¡°Ô Á¤È®Çϰí È¿°úÀûÀÎ ½Å°æÇÐÀû Ä¡·á¸¦ Á¦°øÇÏ´Â ¸ÂÃãÇü ÀÇ·á ¾à¼ÓÀ» ÇØÄ¥ °ÍÀÔ´Ï´Ù.

À¯ÀüüÇÐ ¹× ºÐÀÚÁø´ÜÇÐÀÇ Áøº¸

À¯ÀüüÇÐ ¹× ºÐÀÚÁø´ÜÇÐÀÇ Áøº¸´Â À¯ÀüÀÚ º¯ÀÌ ¹× ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Á¤È®ÇÑ µ¿Á¤À» °¡´ÉÇÏ°Ô Çϰí, ½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á¿¡ Çõ¸íÀ» °¡Á®¿Ô½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½Å¿¡ ÀÇÇØ °£Áú, ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´ µîÀÇ Áúȯ¿¡ ´ëÇÑ ¸ÂÃãÇü Ä¡·á°¡ °¡´ÉÇØÁ® È¿´ÉÀÇ Çâ»ó°ú ºÎÀÛ¿ëÀÇ °æ°¨ÀÌ ½ÇÇöµÇ¾ú½À´Ï´Ù. Á¶±â Áø´Ü ¹× À§Çè ¿¹ÃøÀº »çÀüȰ¼º Ä¡·á¸¦ °­È­Çϰí À¯ÀüÀÚ Ç¥Àû Ä¡·á´Â Áö±Ý±îÁö Ä¡·áÇÒ ¼ö ¾ø¾ú´ø Áúº´¿¡ Èñ¸ÁÀ» ÁÝ´Ï´Ù. ÀÌ µÎ °¡Áö°¡ ÇÔ²² °³ÀÎÈ­µÈ µ¥ÀÌÅÍ ÁÖµµÀÇ ½Å°æ°Ç°­¿¡ ´ëÇÑ º¯È­°¡ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù.

º¹ÀâÇÑ ±ÔÁ¦ »óȲ

º¹ÀâÇÑ ±ÔÁ¦ »óȲÀº ½Å°æÇп¡¼­ ¸ÂÃãÇü ÀÇ·áÀÇ ÁøÀüÀ» Å©°Ô ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ½ÂÀÎ ÇÁ·Î¼¼½º, ´ÜÆíÈ­µÈ ¼¼°è ±âÁØ, ½Å±â¼ú¿¡ ´ëÇÑ ÀûÀÀ Áö¿¬Àº ±â¼ú Çõ½Å°ú ȯÀÚ Á¢±ÙÀ» ´ÊÃß°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ µ¥ÀÌÅÍ ¹× ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ ±ÔÁ¦ÀÇ ¸ðÈ£ÇÔÀº ÀÓ»ó ÅëÇÕÀ» ´õ¿í º¹ÀâÇÏ°Ô ¸¸µì´Ï´Ù. ÀÌ·¯ÇÑ À庮Àº ÅõÀÚ¸¦ ¾ïÁ¦ÇÏ°í °øµ¿ ¿¬±¸¸¦ ¾ïÁ¦ÇÏ¸ç ¸ÂÃãÇü Ä¡·á ¿É¼ÇÀ» Á¦ÇÑÇÏ¸ç ±Ã±ØÀûÀ¸·Î °¡Àå ÇÊ¿äÇÑ È¯ÀÚ¿¡°Ô Á¤È®Çϰí È¿°úÀûÀÎ ½Å°æÇÐÀû Ä¡·á¸¦ Á¦°øÇÏ´Â ÁøÀüÀ» ¹æÇØÇÕ´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19ÀÇ ´ëÀ¯ÇàÀº Á¤¹Ð Ä¡·á ¹× ¿ø°Ý Áø´ÜÀÇ Çʿ伺À» °­Á¶ÇÔÀ¸·Î½á ½Å°æÇп¡¼­ ¸ÂÃãÇü ÀÇ·áÀÇ µµÀÔÀ» °¡¼ÓÈ­Çß½À´Ï´Ù. ¿ø°Ý ÀÇ·á, µðÁöÅÐ Çコ Ç÷§Æû, À¯Àüü ¿¬±¸ÀÇ ±â¼ú Çõ½Å¿¡ ¹ÚÂ÷°¡ °¡ÇØÁ®, ÇコÄɾîÀÇ È¥¶õ¿¡µµ ºÒ±¸Çϰí, ÁÖ¹® Á¦ÀÛÀÇ ½Å°æÇÐÀû Ä¡·á°¡ °¡´ÉÇÏ°Ô µÇ¾ú½À´Ï´Ù. ±×·¯³ª ÀÚ¿øÀÇ À¯¿ë¼º ¹× ÀÓ»ó½ÃÇèÀÇ Áö¿¬Àº ÀϽÃÀûÀ¸·Î Áøº¸¸¦ ¹æÇØÇß½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î, ÀÌ À§±â´Â ½Å°æÁúȯ °ü¸®¿¡¼­ °³ÀÎÈ­µÈ Á¢±ÙÀÇ °¡Ä¡¸¦ °­Á¶Çϰí Äɾî Á¦°ø¿¡¼­ ź·Â¼º°ú ÀûÀÀ·ÂÀ» Ű¿ü½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ¾ËÃ÷ÇÏÀ̸Ӻ´ ºÐ¾ß°¡ ÃÖ´ë°¡ µÉ Àü¸Á

¾ËÃ÷ÇÏÀ̸Ӻ´ ºÐ¾ß´Â º¸´Ù È¿°úÀûÀÎ ¸ÂÃãÇü ÀÇ·á°¡ ½Ã±ÞÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸ÂÃãÇü ÀÇ·á´Â À¯ÀüüÇÐ ¹× ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÀÌ¿ëÇÑ Á¶±â ¹ß°ß ¹× ¸ÂÃãÇü Ä¡·á Àü·«À» °¡´ÉÇÏ°Ô Çϸç, ÀÌ´Â ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ ÁøÇà °ü¸®¿¡ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ¿¬±¸ ÅõÀÚ Áõ°¡ ¹× ±â¼úÀÇ Áøº¸·Î ÀÌ ºÐ¾ß´Â Á¤¹Ð Áø´Ü°ú Ä¡¹ÐÇÑ °³ÀÔÀ¸·ÎºÎÅÍ ÇýÅÃÀ» ¹Þ¾Æ ȯÀÚÀÇ °á°ú¸¦ ´ëÆø °³¼±Çϰí, °£º´Àΰú ÇコÄÉ¾î ½Ã½ºÅÛÀÇ ºÎ´ãÀ» °æ°¨ÇÕ´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ºÐ¾ßÀÇ CAGRÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»ó

¿¹Ãø ±â°£ µ¿¾È ¼öõ °³ÀÇ À¯ÀüÀÚ ¸¶Ä¿¸¦ µ¿½Ã¿¡ ºÐ¼®ÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ºÐ¾ß°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ±â¼úÀº Áúº´ ƯÀÌÀû ¹ÙÀÌ¿À¸¶Ä¿¸¦ È®ÀÎÇÏ°í °³º° ½Å°æÇÐÀû ÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â Ä¡·á¸¦ ¼öÇàÇÏ´Â µ¥ À־ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¶±â Áø´Ü ¹× ¸ÂÃãÇü ÀÇ·á ¼±ÅÃÀ» À§ÇØ ÀÓ»ó ÇöÀå ä¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç ½ÃÀåÀÇ ÀáÀç·ÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â °³º°È­ ½Å°æÇÐ ¿ëµµÀÇ È®ÀåÀ» Áö¿øÇÏ´Â È®Àå °¡´ÉÇÏ°í ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¾öû³­ ȯÀÚ ¼ö, ÀÇ·á ÅõÀÚ Áõ°¡, ½Å°æ Áúȯ¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡·Î ÀÎÇØ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áß±¹, Àεµ, ÀϺ» µîÀÇ ±¹°¡µéÀº ÷´Ü Áø´Ü ±â¼ú°ú ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀ» ºü¸£°Ô µµÀÔÇϰí ÀÖ½À´Ï´Ù. À¯Àüü ¿¬±¸¿Í ÇコÄɾîÀÇ µðÁöÅÐÈ­¸¦ ÃßÁøÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë ¹× ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¼¼°è ½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á Àü¸Á¿¡¼­ Áß¿äÇÑ ÃßÁø·ÂÀÌ µÇ¾ú½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â °ß°íÇÑ ¿¬±¸ ÀÎÇÁ¶ó, ³ôÀº ÇコÄɾî ÁöÃâ, Çõ½Å ±â¼úÀÇ Á¶±â µµÀÔÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ÀÌ Áö¿ªÀº Çмú±â°ü, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, ÀÇ·á Á¦°øÀÚ °£ÀÇ °­·ÂÇÑ °øµ¿¿¬±¸¿¡ ÀÇÇÑ ÇýÅÃÀ» ¹Þ°í ÀÖÀ¸¸ç, À¯Àüü ¹× ºÐÀÚÁø´Ü ÅøÀÇ °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. À¯¸®ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× ¾ËÃ÷ÇÏÀ̸Ӻ´À̳ª ´Ù¹ß¼º °æÈ­Áõ µî ½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ¸ÂÃãÇü ÀÇ·á ¼ö¿ä¸¦ ´õ¿í ¹Ð¾î ¿Ã¸®°í ºÏ¹Ì¸¦ ¼ºÀå ¸®´õ·Î ÀÚ¸®¸Å±èÇϵµ·Ï Çϰí ÀÖ½À´Ï´Ù.

¹«·á ÁÖ¹®À» ¹Þ¾Æ¼­ ¸¸µå´Â ¼­ºñ½º :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå Porter's Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á ½ÃÀå : Ä¡·á À¯Çüº°

Á¦6Àå ¼¼°èÀÇ ½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á ½ÃÀå : ±â¼úº°

Á¦7Àå ¼¼°èÀÇ ½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á ½ÃÀå : ¿ëµµº°

Á¦8Àå ¼¼°èÀÇ ½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦9Àå ¼¼°èÀÇ ½Å°æÇÐ¿ë ¸ÂÃãÇü ÀÇ·á ½ÃÀå : Áö¿ªº°

Á¦10Àå ÁÖ¿ä ¹ßÀü

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Personalized Medicine in Neurology Market is accounted for $576.8 billion in 2025 and is expected to reach $1,021.1 billion by 2032 growing at a CAGR of 8.5% during the forecast period. Personalized medicine in neurology is a patient-centered approach that tailor's diagnosis, treatment, and prevention strategies to an individual's unique genetic, biomarker, environmental, and lifestyle profile. It moves beyond the "one-size-fits-all" model by integrating advanced technologies like genomics, neuroimaging, and data analytics to understand disease mechanisms at a personal level. This approach enhances precision in managing neurological disorders such as epilepsy, Alzheimer's disease, and multiple sclerosis, improving outcomes and minimizing side effects. Personalized neurology also fosters early detection and targeted therapies, empowering clinicians to deliver care that is more effective, predictive, and responsive to each patient's distinct neurological makeup.

Market Dynamics:

Driver:

Rising Prevalence of Neurological Disorders

The rising prevalence of neurological disorders is accelerating advancements in personalized medicine, transforming neurology into a more precise and patient-centric field. With increased demand, researchers are harnessing genetic, biomarker, and lifestyle data to tailor treatments for conditions like Alzheimer's and Parkinson's. This shift fosters innovation in diagnostics and therapeutics, empowering clinicians to deliver more effective, individualized care-ultimately improving outcomes and quality of life for millions affected by neurological diseases.

Restraint:

High Cost of Personalized Treatments

The high cost of personalized treatments in neurology significantly hinders accessibility and equity in care. Many patients, especially in low-resource settings, cannot afford advanced genomic testing or tailored therapies, leading to disparities in treatment outcomes. This financial barrier slows widespread adoption, limits clinical trials, and discourages investment in scalable solutions. Ultimately, it undermines the promise of personalized medicine to deliver precise, effective neurological care for all individuals.

Opportunity:

Advancements in Genomics and Molecular Diagnostics

Advancements in genomics and molecular diagnostics have revolutionized personalized medicine in neurology by enabling precise identification of genetic mutations and biomarkers. These innovations allow tailored treatments for conditions like epilepsy, Alzheimer's, and Parkinson's, improving efficacy and reducing side effects. Early diagnosis and risk prediction empower proactive care, while gene-targeted therapies offer hope for previously untreatable disorders. Together, they drive a transformative shift toward individualized, data-driven neurological healthcare.

Threat:

Complex Regulatory Landscape

The complex regulatory landscape significantly hampers the advancement of personalized medicine in neurology. Stringent approval processes, fragmented global standards, and slow adaptation to emerging technologies delay innovation and patient access. Regulatory ambiguity around genetic data and biomarkers further complicates clinical integration. These barriers discourage investment, stifle collaboration, and limit tailored treatment options, ultimately impeding progress in delivering precise, effective neurological care to patients who need it most.

Covid-19 Impact

The Covid-19 pandemic accelerated the adoption of personalized medicine in neurology by highlighting the need for precision care and remote diagnostics. It spurred innovation in telemedicine, digital health platforms, and genomic research, enabling tailored neurological treatments despite healthcare disruptions. However, resource diversion and delayed clinical trials temporarily hindered progress. Overall, the crisis underscored the value of individualized approaches in managing neurological conditions, fostering resilience and adaptability in care delivery.

The alzheimer's disease segment is expected to be the largest during the forecast period

The alzheimer's disease segment is expected to account for the largest market share during the forecast period, due to urgent need for more effective, individualized treatments. Personalized medicine enables early detection and tailored therapeutic strategies using genomics and biomarkers, which are especially critical in managing Alzheimer's progression. With increasing research investments and technological advancements, this segment benefits from precision diagnostics and targeted interventions, significantly improving patient outcomes and reducing the burden on caregivers and healthcare systems.

The microarray segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the microarray segment is predicted to witness the highest growth rate, due to its ability to analyze thousands of genetic markers simultaneously. This technology plays a pivotal role in identifying disease-specific biomarkers and tailoring treatments to individual neurological profiles. Its growing adoption in clinical settings for early diagnosis and personalized therapy selection enhances its market potential. As demand for precision medicine rises, microarrays offer scalable, cost-effective solutions that support the expansion of personalized neurology applications.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its vast patient population, increasing healthcare investments, and growing awareness of neurological disorders. Countries like China, India, and Japan are rapidly adopting advanced diagnostic technologies and personalized treatment approaches. Government initiatives promoting genomics research and healthcare digitization further fuel market growth. The region's expanding medical infrastructure and rising demand for tailored therapies make it a key driver in the global neurology personalization landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust research infrastructure, high healthcare spending, and early adoption of innovative technologies. The region benefits from strong collaborations between academic institutions, biotech firms, and healthcare providers, accelerating the development of genomic and molecular diagnostic tools. Favorable regulatory frameworks and increasing prevalence of neurological disorders like Alzheimer's and multiple sclerosis further boost demand for personalized treatments, positioning North America as a growth leader.

Key players in the market

Some of the key players profiled in the Personalized Medicine in Neurology Market include Roche Holding AG, Thermo Fisher Scientific Inc., Novartis AG, Becton, Dickinson and Company (BD), Biogen Inc., Merck & Co., Inc., Johnson & Johnson, Siemens Healthineers, Pfizer Inc., Abbott Laboratories, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Illumina, Inc., Neurocrine Biosciences, Inc., QIAGEN N.V., PerkinElmer, Inc. and Agilent Technologies, Inc.

Key Developments:

In August 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.

In July 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.

Therapy Types Covered:

Technologies Covered:

Applications Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Personalized Medicine in Neurology Market, By Therapy Type

6 Global Personalized Medicine in Neurology Market, By Technology

7 Global Personalized Medicine in Neurology Market, By Application

8 Global Personalized Medicine in Neurology Market, By End User

9 Global Personalized Medicine in Neurology Market, By Geography

10 Key Developments

11 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â